Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at BidaskClub

BidaskClub upgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a sell rating to a hold rating in a research note issued to investors on Thursday morning, BidAskClub reports.

Several other equities research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Aurinia Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, July 16th. Royal Bank of Canada reaffirmed a buy rating and issued a $11.00 target price on shares of Aurinia Pharmaceuticals in a research report on Thursday, August 8th. Finally, HC Wainwright reaffirmed a buy rating and issued a $25.00 target price on shares of Aurinia Pharmaceuticals in a research report on Tuesday, June 4th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $15.65.

NASDAQ:AUPH opened at $5.90 on Thursday. The company has a 50-day moving average price of $6.22 and a 200-day moving average price of $6.37. Aurinia Pharmaceuticals has a 12 month low of $5.06 and a 12 month high of $7.85. The stock has a market cap of $517.92 million, a price-to-earnings ratio of -7.76 and a beta of 1.09.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.02). Aurinia Pharmaceuticals had a negative return on equity of 50.08% and a negative net margin of 13,231.97%. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.05 million. On average, equities research analysts expect that Aurinia Pharmaceuticals will post -0.68 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of the stock. Toronto Dominion Bank increased its stake in shares of Aurinia Pharmaceuticals by 26.3% in the 2nd quarter. Toronto Dominion Bank now owns 12,355 shares of the biotechnology company’s stock worth $81,000 after acquiring an additional 2,575 shares in the last quarter. Lindbrook Capital LLC increased its stake in Aurinia Pharmaceuticals by 200.0% during the 1st quarter. Lindbrook Capital LLC now owns 6,000 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 4,000 shares in the last quarter. Vanguard Group Inc. increased its stake in Aurinia Pharmaceuticals by 18.6% during the 2nd quarter. Vanguard Group Inc. now owns 29,020 shares of the biotechnology company’s stock valued at $191,000 after purchasing an additional 4,549 shares in the last quarter. A.R.T. Advisors LLC increased its stake in Aurinia Pharmaceuticals by 44.9% during the 2nd quarter. A.R.T. Advisors LLC now owns 18,395 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 5,700 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new stake in Aurinia Pharmaceuticals during the 1st quarter valued at about $45,000. Institutional investors own 32.52% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Recommended Story: How is a Moving Average Calculated?

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.